Siopel Cream
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Siopel Cream
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Cetrimide 0.3% w/w
Dimeticone 1000 10% w/w
3 PHARMACEUTICAL FORM
A smooth, white homogeneous cream
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
An effective water repellent barrier cream with antiseptic properties, useful whenever the skin needs to be protected from water-soluble irritants.
4.2 Posology and method of administration
Wash and dry the skin. Apply the cream sparingly and massage well into the skin. Apply three to five times daily for three to four days then once or twice daily.
4.3 Contraindications
Siopel cream is contraindicated for patients who have previously shown a hypersensitivity reaction to cetrimide preparations.
4.4 Special warnings and precautions for use
For topical application only. Keep out of the eyes and avoid contact with the brain, meninges or middle ear. Do not use in body cavities or as an enema.
Do not use on skin that is acutely inflamed or weeping, or before the skin has been cleansed of contaminating irritants.
Siopel cream contains Arachis oil (peanut oil) and should not be applied by patients known to be allergic to peanut. As there is a possible relationship between allergy to peanut and allergy to Soya, patients with Soya allergy should also avoid Siopel cream.
4.5 Interaction with other medicinal products and other forms of interaction
None have been reported or are known.
4.6 Fertility, pregnancy and lactation
There is no evidence of any adverse effects on the foetus arising from the use of Siopel cream during pregnancy and therefore no special precautions are recommended.
4.7 Effects on ability to drive and use machines
None have been reported or are known.
4.8 Undesirable effects
Irritative skin reactions can occasionally occur and hypersensitivity to cetrimide preparations has been reported, usually developing after repeated applications, but is rare. Should such reactions occur, stop application of the product.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system in the United Kingdom: Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard
4.9 Overdose
It seems unlikely that systemic toxicity will occur from accidental ingestion of the cream. However, in the event of large quantities being swallowed, carry out gastric lavage with milk, raw egg, gelatin or mild soap and apply supportive measure as appropriate. Do not induce vomiting.
Central paralysis cannot be countered by curare antagonists or CNS stimulants but sympathomimetic drugs have been given.
Mechanically assisted ventilation with oxygen may be necessary. Persistent convulsions may be controlled with cautious doses of diazepam or a shortacting barbiturate. Do not give alcohol in any form.
5.1 Pharmacodynamic properties
Siopel cream is a topical agent for application to intact skin only, and is not intended to be administered by any other route.
Dimeticone 1000 is strongly substantive, binding firmly to the skin surface. There is no evidence of percutaneous absorption and in common with other silicone fluids, is considered to be physiologically inert. There are, as a consequence, no general pharmacological or pharmacokinetic studies available on dimeticone.
Studies with cetrimide have shown it to be active against a wide range of vegetative bacteria, both Gram positive and Gram negative, including Staph. aureus the commonest cause of infection in wounds and burns. Certain Gram negative bacteria, particularly strains of Pseudomonas and Porteus remain the least susceptible of the pathogenic bacteria to cetrimide, requiring a higher concentration than other species to produce an effective kill. Cetrimide is cationic in nature, binding strongly to skin and other tissues thus absorption is negligible.
5.2 Pharmacokinetic properties
Dimeticone 1000 - see section 5.1
Cetrimide:- Isomaa has studied the absorption, distribution and excretion of orally administered 14C-labelled cetrimide in female rats. Approximately 80% of the dose of radioactivity was found in the gastro-intestinal tract 8 hours after administration. Only small amounts were found in the blood plasma and approximately 2% was excreted in the bile during the 12 hours after treatment. The low levels of radioactivity in the serum and bile, together with the large amounts of the antiseptic found in the gastro-intestinal tract, indicate poor intestinal absorption of cetrimide. Only small amounts of radioactivity were found in the liver, kidneys, spleen, heart, lungs and skeletal muscle, and the tissue radioactivity decline rapidly, only traces being found in the tissues 4 days after administration. Within 3 days of ingestion, 92% of the administered radioactivity had been excreted in the faeces and 1% in the urine. No radioactivity was found in the expired CO2 collected during day 1 after administration. Thin-layer chromatography of bile and urine samples indicated that cetrimide was metabolised to some extent in the rat.
5.3 Preclinical safety data
None stated
PHARMACEUTICAL PARTICULARS
6
6.1 List of excipients
Arachis Oil
Butylated Hydroxytoluene Cetostearyl Alcohol Anhydrous Citric Acid Methyl Parahydroxybenzoate Purified Water
6.2 Incompatibilities
Cetrimide is incompatible with soap and other anionic agents.
6.3 Shelf life
4 years
6.4 Special precautions for storage
Store below 25°C
6.5 Nature and contents of container
Aluminium tube (50g)
6.6 Special precautions for disposal
For topical application only. See also section 4.4
7 MARKETING AUTHORISATION HOLDER
Derma UK Ltd Unit 10, Arc Progress Mill Lane Stotfold Bedfordshire SG5 4NY United Kingdom
8 MARKETING AUTHORISATION NUMBER(S)
PL 19876/0010
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
31/08/1998
10
DATE OF REVISION OF THE TEXT
12/07/2016